Inside Pfizer's Oncology Performance Ahead of Q4 Results

Pfizer's oncology franchise — roughly 28% of revenues — grew 7% in the first nine months of 2025, aided by the 2023 Seagen acquisition (Adcetris, Padcev, Tukysa, Tivdak) which contributed meaningfully in the period; Q4 performance is expected to be buoyed by Xtandi, Lorbrena and the Braftovi‑Mektovi combo but offset by declines in Ibrance and Inlyta amid generic competition and Medicare Part D redesign. Management is likely to discuss ADC dynamics, biosimilars growth and late‑stage candidates (atirmociclib, vepdegestrant, sigvotatug vedotin, sasanlimab) on the Feb. 3 call. From a valuation and estimates perspective Pfizer trades at a forward P/E of 8.40 versus 17.56 for the industry, and the Zacks 2026 EPS consensus fell from $3.14 to $3.02 over 60 days; Zacks currently assigns a #4 (Sell) rank.

Analysis

Market structure: Pfizer’s oncology mix (28% of revenue) benefits from Seagen’s ADCs and biosimilars growth, but Medicare Part D redesign and generic Ibrance pressure transfer pricing power toward incumbents with patented PD-(L)1 and PARP franchises (MRK, AZN). Expect modest slowing in unit price inflation across U.S. oncology sales and share shifts into PD-(L)1/PARP therapies; Padcev momentum can offset Adcetris weakness but not fully replace lost Ibrance cash in 2026 without new approvals.

Risk assessment: Near-term tail risks include an adverse FDA/EU decision on sasanlimab or ADC safety signals and deeper Medicare policy changes—each could knock 5–15% off annual oncology revenue in downside scenarios. Immediate risk window is Feb 3 Q4 print and 30–90 days for regulatory news; medium-term (6–18 months) exposure comes from biosimilar/generic rollouts and patent expiries.

Trade implications: Tactical capital should favor relative winners: allocate to AZN/MRK for 6–12 months to capture secular oncology growth while using hedges on PFE around Feb 3. Use option collars around earnings to own PFE cheaply (3–6 month collars) and sized small (2–4% of portfolio) to limit event risk; consider a long AZN vs short PFE pair for 3–9 months to exploit valuation gap.

Contrarian angles: The market likely overprices Medicare risk into PFE such that forward P/E ~8.4 discounts steady buybacks/dividend cash flow; if Q4 shows >5% organic oncology growth (ex-Ibrance) and management holds guidance, re-rating is probable. Conversely, consensus underestimates upside from Padcev share gains and biosimilars expansion—positive readouts or approvals could trigger a sharp catch-up rally.

Key Decisions for Investors

• Establish a 3% long position in PFE ahead of Feb 3 earnings financed via a 6-week collar: buy shares, sell 6-week calls 6–8% OTM and buy 6-week puts 8–12% OTM; hold 3–6 months and increase to 5% only if Q4 organic oncology growth (ex-Ibrance) >+5% and guidance is stable.
• Implement a pair trade: go long AZN 2.5% and short PFE 2.5% for a 6–12 month horizon to capture AZN’s stronger oncology cadence; unwind if AZN underperforms PFE by >10% within 3 months or upon major pipeline setback.
• Buy MRK long (2% position) as a convex play on Keytruda momentum; target add-on if MRK pulls back >8% or if Keytruda growth in Q4 beats consensus by >200bps; hold 6–12 months.
• Prepare a trigger-based short: if consensus 2026 EPS for PFE drops below $2.80 or if FDA/EU rejects sasanlimab, initiate a 2% short or buy 6-month deep ITM puts sized to that exposure; monitor regulatory decisions and Feb 3 guidance as immediate catalysts.